Labcorp's advanced melanoma CDx secures FDA approval

Labcorp's advanced melanoma companion diagnostic (CDx) has received FDA approval, enabling targeted therapy identification for patients with specific BRAF mutations in melanoma. This next-generation sequencing test supports precision oncology by detecting mutation types that guide effective treatment decisions.

This Wire brief sits within Fusion42's coverage of Biotech.